Pluri Inc. · NASDAQ:PLUR
Pluri — Pluristem Therapeutics — Corporate Update (May 2021)
20 slides from Pluri's corporate update, May 3, 2021
Slide 1: Analyst and Investor Call - HCT Phase I Topline Results
- Analyst and Investor Call - HCT Phase | Topline Results May 3, 2021 Inspired by Life
Slide 2: Presenters and agenda
& a Yaky Yanay, Nitsan Halevy, MD Jacob Rowe, MD, FACP Chen Franco-Yehuda, CEO and President Chief Medical Officer Director Hematology, CFO Shaare Zedek Medical Center, Jerusalem Hematological deficiencies Phase | HCT — Clinical Financial overview PLX-R18 product candidate topline rj
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss that PLX cells may provide a sa
Slide 4: Hematological Deficiencies
Hematological Deficiencies Phase | . ' ed Open-label, dose-escalation study to =, evaluate the safety of intramuscular > injections of PLX-18 in subjects with 2 incomplete hematopoietic recovery a. x following Hematopoietic Cell . Transplantation (HCT)
Slide 5: The Need: Poor Graft Function
The Need: Poor Graft Functions g ¢ In patients suffering from a life-threatening condition of incomplete hematopoietic recovery, graft function remain poor, in which they fail to develop satisfactory blood counts in some or all blood cell lineages ¢ Available current treatments target only one of th
Slide 6: PLX-R18: Hematological Deficiencies
PLX-R18: Hematological Deficiencies gG- PLX-R18 is designed to stimulate the regeneration of damaged bone marrow to produce all blood cell lineages — white, red and platelets Preclinical studies: Significant recovery of the three blood cell types PLX-R18: Mechanism of Action (IMoA) Pit H ! Hy 0 H H
Slide 7: PLX-R18
PLX-R18 tem Manufactured in 3D cell expansion system, in our GMP certified cell manufacturing facility | PLX-R18 is the first product candidate that | Pluristem manufactures using our developed i serum-free media
Slide 8: PLX Platform
PLX Platform g- Clinical pipeline Developments Next generation PLX-PAD PLX-R18 PLX Immune Genome-Editing Solutions for PLX Cells <3 i" _ —_ — 4 Phase III — Muscle ' Phase | — HCT regeneration following coneeeeeeeeneee i Hip Fracture Animal Rule-ARS | es (Acute Radiation i i Phase Il — ARDS i Syndrom
Slide 9: Clinical Pipeline
Clinical Pipeline PRODUCT FOCUS Muscle Injuries PLX-PAD Inflammatory Diseases PLX-R18 Hematological Deficiencies *Via FDA Animal Rule INDICATION Muscle Regeneration following Hip Fracture ARDS associated with COVID-19 Chronic Graft vs Host Disease (cGvHD) Acute Radiation Syndrome (ARS)* Hematopoieti
Slide 10: PLX-R18 as a Treatment for Hematological Deficiencies
PLX-R18 as a Treatment for Hematological Deficiencies A Phase | study (n= 21 patients) of patients with persistent deficiency of at least one blood cell types (platelets, hemoglobin and neutrophil counts) suffering from poor graft function following HCT. PLX-R18 was well-tolerated with a favorable s
Slide 11: PLX-R18-HCT-01: Open-label, Dose-Escalation, Phase I Study
PLX-R18-HCT-01: Open-label, Dose-Escalation, Phase I Study (NCT03002519) Study population: Incomplete hematopoietic recovery persisting >3 months after HCT Inclusion Criteria: PLT <50,000/1L and/or Hb <8g/dL and/or ANC <1,000/pL Sample Size: 21 patients Countries: USA & Israel » » » Study Endpoints:
Slide 12: Patients Clinical Characteristics (n=21)
Patients Clinical Characteristics (n=21) ge Variables Value Median Days From HCT to Treatment (range) 236 (118-872) Mean Patients Age (range) 56 (29-75) Gender, male (%) 12(57%) HCT Type, allogeneic (%) 19 (90%) Disease Types Acute Lymphoblastic Leukemia 7 (33%) Acute Myelogenous Leukemia 3 (14%) Bu
Slide 13: Improvement in All Three Blood Cell Lineages
Improvement in All Three Blood Cell Lineages Hemoglobin Neutrophil Platelet 120 12 21 o ii = 80 a Ww + “4 ro) = 3 : 2 a ®B | - BRR FA. + 8 9 £ 2 40 £ 2 s r 2 = > 1Mcell = cells/kg 8 > 2M cells/kg 0 —> 4M cells/kg 7 50 100 150 + *<0.05, ** <0.01 * SEM, standard error mean * Mixed Model Repeated Measu
Slide 14: Response to Treatment
Response to Treatment At 6-month follow-up, 10 patients that were treated with PLX-R18 showed response in all 3 blood cell types Response defined as: Platelet > 50,000/uL and Hemoglobin > 8 g/dL and Neutrophil 2 1000/pL 25 4 20 4 15 4 10 4 Number of Patients Response to Treatment G missing 3 paramet
Slide 15: Substantial Reduction in Transfusion Dependence
Substantial Reduction in Transfusion g- Transfusion Dependence At 6-months, 46% of the patients treated with PLX-R18 become P| 3 transfusion independent | Number of Subjects Baseline Month 6
Slide 16: Jacob M. Rowe, MD, FACP - Disclosures
Jacob M. Rowe, MD, FACP - Disclosures ¢ Member of Pluristem HCT clinical study advisory board
Slide 17: Jacob M. Rowe, MD, FACP
Jacob M. Rowe, MD, FACP Patel gG- 90 Current position: 80 * Shaare Zedek Medical Center in Jerusalem, Hematology 2 40 * — Annand Pinky Sohn Chair in Hemato-Oncology £ * — Editor-in-Chief, Haematologica a 60 50}~ Former positions: 40 0 50 100 150 ¢ University of Rochester Medical Center Days from PLX
Slide 18: What is Next
What is Next ¢ One year follow up ¢ We intend to proceed the clinical development of PLX-R18 with the goal of establishing i i i
Slide 19: Financials
Financials Ge Cash: ~$74 million | EIB non-dilutive financing (as of March 31, 2021) || agreement: First tranche of €20M _— | expected during H1 of 2021 * calendar year We nl mK rn, cit be
Slide 20: Thank you
Thank you Israel +972-74-710-8600 U.S. +1-347-973-2098 Germany +49-30-2215-0786